Clinical and Biochemical Evidence of Control of Prostate Cancer at 5 Years After External Beam Radiation
作者： Gerald E.* Hanks , W. Robert Lee , Timothy E. Schultheiss
DOI: 10.1016/S0022-5347(01)67073-3
关键词:
摘要: AbstractPurpose: We demonstrate the 5-year survival rate for patients with prostate cancer treated by irradiation, value of conformal technique and specific antigen (PSA) doubling times after irradiation.Materials Methods: The outcome 502 consecutive stages T1 to T3 irradiation alone is reported. PSA before failure are reported 13 posttreatment 93 in whom radiation failed.Results: actuarial biochemical freedom from disease (PSA nadir 1.5 or less not increasing) at 5 years was 44 percent all patients, 50 treatment group 39 conventional therapy group. were variable, 42 greater than 12 months.Conclusions: excellent. is...
jurology.com 参考文章(15)
A W Partin, P C Walsh, J I Epstein, C R Pound, J Q Clemens, Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years Urologic Clinics of North America. ,vol. 20, pp. 713- 725 ,(1993) , 10.1016/S0094-0143(21)00924-1
A.L. Zietman, J.J. Coen, W.U. Shipley, C.G. Willett, J.T. Efird, Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome The Journal of Urology. ,vol. 151, pp. 640- 645 ,(1994) , 10.1016/S0022-5347(17)35036-X
T M Pisansky, S S Cha, J D Earle, E D Durr, T F Kozelsky, H S Wieand, J E Oesterling, Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. Journal of Clinical Oncology. ,vol. 11, pp. 2158- 2166 ,(1993) , 10.1200/JCO.1993.11.11.2158
Gerald E. Hanks, John M. Krall, Alexandra L. Hanlon, Sucha O. Asbell, Miljenko V. Pilepich, Jean B. Owen, Patterns of care and rtog studies in prostate cancer: Long-term survival, hazard rate observations, and possibilities of cure International Journal of Radiation Oncology*Biology*Physics. ,vol. 28, pp. 39- 45 ,(1994) , 10.1016/0360-3016(94)90139-2
Joseph E. Oesterling, The Use of Prostate-Specific Antigen in Staging Patients With Newly Diagnosed Prostate Cancer JAMA: The Journal of the American Medical Association. ,vol. 269, pp. 57- 60 ,(1993) , 10.1001/JAMA.1993.03500010067033
Gerald E. Hanks, Optimizing the radiation treatment and outcome of prostate cancer International Journal of Radiation Oncology Biology Physics. ,vol. 11, pp. 1235- 1245 ,(1984) , 10.1016/0360-3016(85)90239-1
Gerald E. Hanks, Carlos A. Perez, M. Kozar, Sucha O. Asbell, Miljenko V. Pilepich, Thomas F. Pajak, PSA confirmation of cure at 10 years of T1B, T2, N0, M0 prostate cancer patients treated in RTOG protocol 7706 with external beam irradiation International Journal of Radiation Oncology Biology Physics. ,vol. 30, pp. 289- 292 ,(1994) , 10.1016/0360-3016(94)90006-X
Peter P. Lai, Carlos A. Perez, Susan J. Shapiro, Mary A. Lockett, Carcinoma of the prostate stage B and C: lack of influence of duration of radiotherapy on tumor control and treatment morbidity. International Journal of Radiation Oncology Biology Physics. ,vol. 19, pp. 561- 568 ,(1990) , 10.1016/0360-3016(90)90481-X
Benjamin W. Corn, Gerald E. Hanks, Timothy E. Schultheiss, Margie A. Hunt, W.Robert Lee, Lawrence R. Coia, Conformal treatment of prostate cancer with improved targeting: superior prostate-specific antigen response compared to standard treatment. International Journal of Radiation Oncology Biology Physics. ,vol. 32, pp. 325- 330 ,(1995) , 10.1016/0360-3016(94)00618-U
R. Jeffrey Lee, William T. Sause, Surgically staged patients with prostatic carcinoma treated with definitive radiotherapy : fifteen-year results Urology. ,vol. 43, pp. 640- 644 ,(1994) , 10.1016/0090-4295(94)90178-3